{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:04:33Z","timestamp":1786993473364,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.jval.2018.05.005","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T01:50:49Z","timestamp":1532569849000},"page":"1322-1329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease"],"prefix":"10.1016","volume":"21","author":[{"given":"Alan","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn A.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyfrig A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2018.05.005_bib1","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","article-title":"Amyotrophic lateral sclerosis","volume":"390","author":"Van","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2018.05.005_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001447.pub3","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","author":"Miller","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jval.2018.05.005_bib3","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1212\/WNL.0b013e3181bc01a4","article-title":"Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive\/behavioural impairment (an evidence-based review)","volume":"73","author":"Miller","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jval.2018.05.005_bib4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"16","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jval.2018.05.005_bib5","unstructured":"Motor Neurone Disease Association. MND treatment trials. Available from: http:\/\/www.mndassociation.org\/research\/mnd-research-and-you\/treatment-trials\/. [Accessed October 2, 2016]."},{"key":"10.1016\/j.jval.2018.05.005_bib6","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s13311-015-0339-9","article-title":"Recent advances and the future of stem cell therapies in amyotrophic lateral sclerosis","volume":"12","author":"Goutman","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jval.2018.05.005_bib7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40273-016-0478-9","article-title":"Economic studies in motor neurone disease: a systematic methodological review","volume":"35","author":"Moore","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2018.05.005_bib8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jval.2012.10.010","article-title":"Mapping to obtain EQ-5D utility values for use in NICE health technology assessments","volume":"16","author":"Longworth","year":"2013","journal-title":"Value Health"},{"issue":"Suppl. 1","key":"10.1016\/j.jval.2018.05.005_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40273-017-0545-x","article-title":"A review of generic preference-based measures for use in cost-effectiveness models","volume":"35","author":"Brazier","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2018.05.005_bib10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/21678421.2013.872149","article-title":"Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis","volume":"15","author":"Jones","year":"2014","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.jval.2018.05.005_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0022-510X(01)00616-5","article-title":"Patients\u2019 health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis","volume":"191","author":"Kiebert","year":"2001","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jval.2018.05.005_bib12","unstructured":"National Institute for Health and Care Excellence. Process and methods: guide to the methods of technology appraisal. 2013. Available from: https:\/\/www.nice.org.uk\/process\/pmg9. [Accessed March 24, 2017]."},{"key":"10.1016\/j.jval.2018.05.005_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1477-7525-11-151","article-title":"Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database","volume":"11","author":"Dakin","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2018.05.005_bib14","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s40273-015-0312-9","article-title":"The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: explanation and elaboration","volume":"33","author":"Petrou","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2018.05.005_bib15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jval.2016.11.006","article-title":"Mapping to estimate health-state utility from non\u2013preference-based outcome measures: an ISPOR Good Practices for Outcomes Research Task Force Report","volume":"20","author":"Wailoo","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2018.05.005_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-11-35","article-title":"Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson\u2019s disease","volume":"11","author":"Dams","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2018.05.005_bib17","doi-asserted-by":"crossref","first-page":"e002798","DOI":"10.1136\/bmjopen-2013-002798","article-title":"Mapping the 12-item multiple sclerosis walking scale to the EuroQol 5-dimension index measure in North American multiple sclerosis patients","volume":"3","author":"Sidovar","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jval.2018.05.005_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jval.2018.05.005_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/14660820410020187","article-title":"Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial","volume":"5","author":"Leigh","year":"2004","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"10.1016\/j.jval.2018.05.005_bib20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/14660820410021339","article-title":"Integrating preferences into health status assessment for amyotrophic lateral sclerosis: the ALS Utility Index","volume":"6","author":"Beusterien","year":"2005","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"10.1016\/j.jval.2018.05.005_bib21","unstructured":"Trajectories of Outcomes in Neurological Conditions. Motor Neurone Disease. Available from: https:\/\/tonic.thewaltoncentre.nhs.uk\/ [Accessed March 24, 2017]."},{"key":"10.1016\/j.jval.2018.05.005_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hec.3564","article-title":"Valuing health-related quality of life: an EQ-5D-5L value set for England","volume":"27","author":"Devlin","year":"2018","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2018.05.005_bib23","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/jnnp-2012-304701","article-title":"Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis","volume":"84","author":"Franchignoni","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jval.2018.05.005_bib24","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1212\/WNL.48.2.332","article-title":"Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale","volume":"48","author":"Bradley","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.jval.2018.05.005_bib25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1477-7525-9-82","article-title":"Rasch analysis of the Hospital Anxiety and Depression Scale (HADS) for use in motor neurone disease","volume":"9","author":"Gibbons","year":"2011","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2018.05.005_bib26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The Hospital Anxiety and Depression Scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.jval.2018.05.005_bib27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2307\/1924766","article-title":"The uses of Tobit analysis","volume":"62","author":"McDonald","year":"1980","journal-title":"Rev Econ Stat"},{"key":"10.1016\/j.jval.2018.05.005_bib28","series-title":"R: A Language and Environment for Statistical Computing","author":"Core Team","year":"2013"},{"key":"10.1016\/j.jval.2018.05.005_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1037\/a0027127","article-title":"Model selection and psychological theory: a discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC)","volume":"17","author":"Vrieze","year":"2012","journal-title":"Psychol Methods"},{"key":"10.1016\/j.jval.2018.05.005_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000351153","article-title":"Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature","volume":"41","author":"Chi\u00f2","year":"2013","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jval.2018.05.005_bib31","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/jnnp.2003.033100","article-title":"A cross sectional study on determinants of quality of life in ALS","volume":"75","author":"Chi\u00f2","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301518322022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301518322022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T02:14:47Z","timestamp":1572747287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301518322022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1098301518322022"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2018.05.005","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2018.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}